Comparison · NCT01643707-da2c1816
Phase 1 vs Phase 2: The Absolute Change in the Proportion of Subjects Diagnosed With SND Before and After Intervention
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Phase 1 vs Phase 2: The Absolute Change in the Proportion of Subjects Diagnosed With SND Before and After Intervention. Trial comparisons, record NCT01643707-da2c1816. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01643707-da2c1816
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.724 | 0.684 | 0.761 | wilson | |
| Risk in group 2 | 0.87 | 0.837 | 0.898 | wilson | |
| Risk difference, group 1 minus group 2 | -0.146 | -0.195 | -0.0959 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.832 | 0.781 | 0.887 | log | |
| Odds ratio, group 1 over group 2 | 0.392 | 0.281 | 0.546 | log | |
| Number needed to treat, for one fewer participant with the outcome on Phase 1 than on Phase 2 | 6.86 | 5.14 | 10.4 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Phase 1 | Control subjects in the South Asia Region. | 368 | 508 | OG000 |
| Group 2 | Phase 2 | Treatment subjects in the South Asia Region | 409 | 470 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- The Absolute Change in the Proportion of Subjects Diagnosed With SND Before and After Intervention
- Description
- The absolute change in the proportion of subjects diagnosed with SND before and after intervention
- Time frame
- Up to 1 year post enrollment
- Population
- Only sites in South Asia participated in both Phase 1 and Phase 2, as such those subjects were included for objective analysis.
Source ClinicalTrials.gov
Trial
- Title
- Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)
- NCT number
- NCT01643707
- Phases
- Conditions
- Sinus Node Dysfunction
- Interventions
- Evidence based guidelines and tools
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Results first posted
- 2021-09-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01643707?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01643707-da2c1816